4-hydroxybenzylcyanide: suicide substrate for dopamine beta-hydroxylase [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
(4-hydroxyphenyl)acetonitrile : A hydroxynitrile that is phenylacetonitrile substituted by a hydroxy group at position 4. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 26548 |
| CHEBI ID | 16667 |
| SCHEMBL ID | 448467 |
| MeSH ID | M0087927 |
| Synonym |
|---|
| HMS1786P20 |
| einecs 238-046-0 |
| brn 1934470 |
| nsc 76080 |
| CHEBI:16667 |
| 4-hydroxybenzeneacetonitrile |
| 4-hydroxyphenylacetic acid nitrile |
| 4-hydroxybenzylcyanide |
| acetonitrile, (p-hydroxyphenyl)- |
| p-hydroxyphenylacetonitrile |
| nsc76080 |
| p-hydroxybenzyl cyanide |
| nsc-76080 |
| (4-hydroxyphenyl)acetonitrile |
| benzeneacetonitrile, 4-hydroxy- |
| inchi=1/c8h7no/c9-6-5-7-1-3-8(10)4-2-7/h1-4,10h,5h |
| acetic acid,(4-hydroxyphenyl),nitrile 4-hydroxy-benzylcyanide |
| 14191-95-8 |
| C03766 |
| 4-hydroxyphenylacetonitrile |
| 4-hydroxybenzyl cyanide |
| 4-hydroxyphenylacetonitrile, 98% |
| acetonitrile, 4-hydroxyphenyl- |
| AC-10551 |
| 7898C7A4-5D46-437F-8474-B1E83F66AFE5 |
| benzeneacetonitrile, 4-hydroxy- (9ci) |
| BMSE000441 |
| H0657 |
| 2-(4-hydroxyphenyl)acetonitrile |
| AKOS000121408 |
| unii-18q5j224rm |
| 18q5j224rm , |
| 4-10-00-00554 (beilstein handbook reference) |
| 4-(cyanomethyl)phenol |
| FT-0618736 |
| FT-0618737 |
| PS-4572 |
| AE-562/40164564 |
| SCHEMBL448467 |
| 3aq , |
| para-hydroxybenzyl cyanide |
| p-hydroxy phenyl acetonitrile |
| alpha-cyano-p-cresol |
| 4-(hydroxy)phenyl acetonitrile |
| p-hydroxybenzylcyanide |
| W-108181 |
| STR01465 |
| mfcd00002383 |
| DTXSID90161856 |
| Z90120144 |
| (4-hydroxy-phenyl)-acetonitrile |
| Q27102019 |
| AM10835 |
| EN300-18729 |
| CS-W016539 |
| HY-W015823 |
| PD158329 |
| Role | Description |
|---|---|
| plant metabolite | Any eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| hydroxynitrile | Any nitrile compound which also contains a hydroxy group. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Pathway | Proteins | Compounds |
|---|---|---|
| taxiphyllin biosynthesis | 2 | 14 |
| dhurrin biosynthesis | 2 | 14 |
| dhurrin biosynthesis | 1 | 14 |
| taxiphyllin biosynthesis | 0 | 14 |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
| AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 2 (28.57) | 18.7374 |
| 1990's | 2 (28.57) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.40) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||